‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff FiercePharma 23:03 Thu, 11 Jun
ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC Pharmaceutical Technology 15:32 Tue, 02 Jun
Talzenna Plus Xtandi Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer Business Wire (Press Release) 13:03 Sat, 30 May
Astellas To Drive Strategic Brands, Pivotal Studies To Fill Xtandi Gap Scrip Pharma Intelligence 07:45 Wed, 27 May
